Treatment guidelines for community-acquired pneumonia in Korea: An evidence-based approach to appropriate antimicrobial therapy

Tuberculosis and Respiratory Diseases

Volumn 67, Issue 4, 2009, Pages 281-302

  Song, Jae Hoon ^a   Jung, Ki Suck ^b   Kang, Moon Won ^c   Kim, Do Jin ^d   Pai, Hyunjoo ^e   Suh, Gee Young ^a   Shim, Tae Sun ^f   Ahn, Joong Hyun ^g   Ahn, Chul Min ^h   Woo, Jun Hee ^f   Lee, Nam Yong ^a   Lee, Dong Gun ^c   Lee, Mi Suk ⁱ   Lee, Sang Moo ^j   Lee, Yeong Seon ^k   Lee, Hyukmin ^l   Chung, Doo Ryeon ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Soonchunhyang University   (South Korea)

^e Hanyang University College of Medicine   (South Korea)

^f University of Ulsan College of Medicine   (South Korea)

^g Bupyeong gu   (South Korea)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Kyung Hee University College of Medicine   (South Korea)

^j Health Insurance Review Agency   (South Korea)

^k Korea Centers for Disease Control and Prevention   (South Korea)

^l Catholic Kwandong University   (South Korea)

more..

Author keywords

Anti bacterial agents; Pneumonia; Practice guideline

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; CARBAPENEM; CEFACLOR; CEFDITOREN; CEFDITOREN PIVOXIL; CEFEPIME; CEFOTAXIME; CEFPODOXIME; CEFPODOXIME PROXETIL; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; GEMIFLOXACIN; GLYCOPEPTIDE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; ROXITHROMYCIN; SULTAMICILLIN; UNINDEXED DRUG;

ABDOMINAL PAIN; ACINETOBACTER; ADENOVIRUS; ALCOHOL CONSUMPTION; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTERIAL PH; ARTIFICIAL VENTILATION; AUTUMN; BETA HEMOLYTIC STREPTOCOCCUS; BODY TEMPERATURE; BREATHING RATE; BRONCHIECTASIS; CEREBROVASCULAR DISEASE; CHLAMYDIA; CHRONIC KIDNEY DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONFUSION; CONGESTIVE HEART FAILURE; COXIELLA BURNETII; DISEASE SEVERITY; DISORIENTATION; DRUG MEGADOSE; ENTEROBACTER; ENVIRONMENTAL EXPOSURE; FLUID THERAPY; GENDER; GLUCOSE BLOOD LEVEL; HAEMOPHILUS INFECTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOME CARE; HOSPITALIZATION; HUMAN; HYPOTENSION; IMMUNOCOMPETENCE; INFLUENZA; INFLUENZA VIRUS A; INTENSIVE CARE UNIT; INTRAVENOUS DRUG ABUSE; KLEBSIELLA; KOREA; LEGIONELLA; LEGIONELLA PNEUMOPHILA; LEPTOSPIRA; LEUKOCYTE COUNT; LIVER DISEASE; LUNG ASPIRATION; MEDICAL SOCIETY; MENTAL DISEASE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; MUSCLE CRAMP; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA; MYCOPLASMA PNEUMONIA; NAUSEA; NEOPLASM; NURSING HOME PATIENT; ORIENTIA TSUTSUGAMUSHI; OXYGEN TENSION; PATIENT CARE; PLEURA EFFUSION; PRACTICE GUIDELINE; PSEUDOMONAS; PSEUDOMONAS PNEUMONIA; PULSE RATE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; RNA VIRUS INFECTION; SEPTIC SHOCK; SODIUM BLOOD LEVEL; STAPHYLOCOCCAL PNEUMONIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; SYSTOLIC BLOOD PRESSURE; THORAX RADIOGRAPHY; THROMBOCYTE COUNT; TREATMENT FAILURE; UREA NITROGEN BLOOD LEVEL; VOMITING;

EID: 70449984550     PISSN: 17383536     EISSN: None     Source Type: Journal    
DOI: 10.4046/trd.2009.67.4.281     Document Type: Review

References (117)

1. Korea National Statistical Office. Annual report on the cause of death statistics 2007: Nationwide. Daejeon: Korea National Statistical Office; 2007.
2. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749-755
3. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001;95:78-82.
4. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44 Suppl 2:S27-72. (Pubitemid 46290553)
5. Jefferson H, Dalton HP, Escobar MR, Allison MJ. Transportation delay and the microbiological quality of clinical specimens. Am J Clin Pathol 1975;64:689-93.
6. Yzerman EP, den Boer JW, Lettinga KD, Schellekens J, Dankert J, Peeters M. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in The Netherlands. J Clin Microbiol 2002;40:3232-3236
7. Rosón B, Fernández-Sabé N, Carratalà J, Verdaguer R, Dorca J, Manresa F, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004;38:222-226
8. Kim S, Sung H, Kim DJ, Kim MN. Clinical relevance of positive NOW (TM) legionella urinary antigen test in a tertiary-care hospital in Korea. Korean J Lab Med 2006;26:93-97
9. van der Eerden MM, Vlaspolder F, de Graaff CS, Groot T, Bronsveld W, Jansen HM, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005;60:672-678
10. Lee JS, Chung JW, Koh Y, Lim CM, Jung YJ, Oh YM, et al. The etiologies and initial antimicrobial therapy outcomes in one tertiary hospital ICU-admitted patient with severe community-acquired pneumonia. Tuberc Respir Dis 2005;59:522-529 (Pubitemid 43372021)
11. Campbell SG, Marrie TJ, Anstey R, Dickinson G, Ackroyd-Stolarz S. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003;123:1142-1150 (Pubitemid 36444372)
12. Hahn TH, Jang MK, Kim SG, Lee JY, Lee JM, Kim DK, et al. The usefulness of quantitative culture of bronchoalveolar lavage fluid in the diagnosis of bacterial pneumonia. Korean J Med 1998;54:820-826
13. Smith MD, Derrington P, Evans R, Creek M, Morris R, Dance DA, et al. Rapid diagnosis of bacteremic pneumococcal infections in adults by using the Binax NOW Streptococcus pneumoniae urinary antigen test: a prospective, controlled clinical evaluation. J Clin Microbiol 2003;41:2810-2813 (Pubitemid 36842263)
14. Murdoch DR, Laing RT, Cook JM. The NOW S. pneumoniae urinary antigen test positivity rate 6 weeks after pneumonia onset and among patients with COPD. Clin Infect Dis 2003;37:153-154
15. Labarere J, Stone RA, Obrosky DS, Yealy DM, Meehan TP, Fine JM, et al. Comparison of outcomes for low-risk outpatients and inpatients with pneumonia: a propensity-adjusted analysis. Chest 2007;131:480-488 (Pubitemid 46280409)
16. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study. Arch Intern Med 2004;164:963-968 (Pubitemid 38581515)
17. Minogue MF, Coley CM, Fine MJ, Marrie TJ, Kapoor WN, Singer DE. Patients hospitalized after initial outpatient treatment for community-acquired pneumonia. Ann Emerg Med 1998;31:376-380 (Pubitemid 28135363)
18. Neill AM, Martin IR, Weir R, Anderson R, Chereshsky A, Epton MJ, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996;51:1010-1016 (Pubitemid 26360177)
19. Labarere J, Stone RA, Scott Obrosky D, Yealy DM, Meehan TP, Auble TE, et al. Factors associated with the hospitalization of low-risk patients with community-acquired pneumonia in a cluster-randomized trial. J Gen Intern Med 2006;21:745-752 (Pubitemid 43973560)
20. Bae JH, Lee MJ, Oh DR, Lee WJ, Kim SK. Modified triage method by pneumonia severity index for patients with community: acquired pneumonia. J Korean Soc Emerg Med 2002;13:129-134
21. Choi SO, Park MS, Kang MH, Lee MK. Evaluation of risk factors for hospitalization and comparison of empiricregimens for efficacy and toxicity to treat community-acquired pneumonia. J Korean Soc Health Syst Pharm 2005;22:36-45.
22. Bont J, Hak E, Hoes AW, Schipper M, Schellevis FG, Verheij TJ. A prediction rule for elderly primary-care patients with lower respiratory tract infections. Eur Respir J 2007;29:969-975 (Pubitemid 46711903)
23. Fine MJ, Hough LJ, Medsger AR, Li YH, Ricci EM, Singer DE, et al. The hospital admission decision for patients with community-acquired pneumonia. Results from the pneumonia Patient Outcomes Research Team cohort study. Arch Intern Med 1997;157:36-44.
24. Yealy DM, Auble TE, Stone RA, Lave JR, Meehan TP, Graff LG, et al. Effect of increasing the intensity of implementing pneumonia guidelines: a randomized, controlled trial. Ann Intern Med 2005;143:881-894
25. Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003;58:377-382 (Pubitemid 36560938)
26. Teramoto S, Yamamoto H, Yamaguchi Y, Hanaoka Y, Ishii M, Hibi S, et al. Lower respiratory tract infection outcomes are predicted better by an age >80 years than by CURB-65. Eur Respir J 2008;31:477-478
27. Aujesky D, Auble TE, Yealy DM, Stone RA, Obrosky DS, Meehan TP, et al. Prospective comparison of three validated prediction rules for prognosis in community-acquired pneumonia. Am J Med 2005;118:384-392 (Pubitemid 40460997)
28. Foley SC, KeUy EM, O'Neill SJ. Audit of the management of patients admitted with community acquired pneumonia. Ir Med J 2006;99:138-140
29. Angus DC, Marrie TJ, Obrosky DS, Clermont G, Dremsizov TT, Coley C, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society Diagnostic criteria. Am J Respir Crit Care Med 2002;166:717-723 (Pubitemid 34971856)
30. Ananda-Rajah MR, Charles PG, Melvani S, Burrell LL, Johnson PD, Grayson ML. Comparing the pneumonia severity index with CURB-65 in patients admitted with community acquired pneumonia. Scand J Infect Dis 2008;40:293-300.
31. Marrie TJ, Huang JQ. Admission is not always necessary for patients with community-acquired pneumonia in risk classes IV and V diagnosed in the emergency room. Can Respir J 2007;14:212-216
32. Valencia M, Badia JR, Cavalcanti M, Ferrer M, Agusti C, Angrill J, et al. Pneumonia severity index class v patients with community-acquired pneumonia: characteristics, outcomes, and value of severity scores. Chest 2007;132:515-522 (Pubitemid 47282383)
33. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med 1998;158:1102-1108 (Pubitemid 28489008)
34. Ramirez JA. Switch therapy in community-acquired pneumonia. Diagn Microbiol Infect Dis 1995;22:219-23.
35. Ramirez JA, Vargas S, Ritter GW, Brier ME, Wright A, Smith S, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999;159:2449-2454 (Pubitemid 29526773)
36. Ramirez JA, Bordon J. Early switch from intravenous to oral antibiotics in hospitalized patients with bacteremic community-acquired Streptococcus pneumoniae pneumonia. Arch Intern Med 2001;161:848-850 (Pubitemid 32225393)
37. Castro-Guardiola A, Viejo-Rodríguez AL, Soler-Simon S, Armengou-Arxé A, Bisbe-Company V, Peñarroja-Matutano G, et al. Efficacy and safety of oral and early-switch therapy for community-acquired pneumonia: a randomized controlled trial. Am J Med 2001;111:367-374
38. Rhew DC, Riedinger MS, Sandhu M, Bowers C, Greengold N, Weingarten SR. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998;114:115-119
39. Halm EA, Fine MJ, Kapoor WN, Singer DE, Marrie TJ, Siu AL. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002;162:1278-1284 (Pubitemid 34595034)
40. Capelastegui A, España PP, Bilbao A, Martinez-Vazquez M, Gorordo I, Oribe M, et al. Pneumonia: criteria for patient instability on hospital discharge. Chest 2008;134:595-600.
41. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998;279:1452-1457
42. Jasti H, Mortensen EM, Obrosky DS, Kapoor WN, Fine MJ. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis 2008;46:550-556 (Pubitemid 351263494)
43. El Moussaoui R, Opmeer BC, de Borgie CA, Nieuwkerk P, Bossuyt PM, Speelman P, et al. Long-term symptom recovery and health-related quality of life in patients with mild-to-moderate- severe community-acquired pneumonia. Chest 2006;130:1165-1172
44. Chang J. Community acquired pneumonia. Korean J Med 2000;58:129-144
45. Hyun I. Treatment of Outpatient community-acquired pneumonia. Korean J Med 2003;64:139-143
46. Bruns AH, Oosterheert JJ, Hak E, Hoepelman AI. Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia. Eur Respir J 2008;32:726-732
47. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient iv. antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996;110:965-971 (Pubitemid 26347611)
48. Léophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community-acquired pneumonia of suspected pneumococcal origin. Respir Med 2004;98:708-720 (Pubitemid 38842773)
49. Rovira E, Martínez-Moragón E, Belda A, Gonzalvo F, Ripollés F, Pascual JM. Treatment of community-acquired pneumonia in outpatients: randomized study of clarithromycin alone versus clarithromycin and cefuroxime. Respiration 1999;66:413-418 (Pubitemid 29431574)
50. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998;92:1032-1039 (Pubitemid 28416834)
51. O'Doherty B, Dutchman DA, Pettit R, Maroli A. Randomized, double-blind, comparative study of grepafloxacin and amoxicillin in the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother 1997;40 Suppl A:73-81. (Pubitemid 28041170)
52. Bruns AH, Oosterheert JJ, Prokop M, Lammers JW, Hak E, Hoepelman AI. Patterns of resolution of chest radiograph abnormalities in adults hospitalized with severe community-acquired pneumonia. Clin Infect Dis 2007;45:983-991 (Pubitemid 47580346)
53. Woo JH, Kang JM, Kim YS, Shin WS, Ryu JH, Choi JH, et al. A prospective multicenter study of community-acquired pneumonia in adults with emphasis on bacterial etiology. Korean J Infect Dis 2001;33:1-7.
54. Chung MH, Shin WS, Kim YR, Kang MW, Kim MJ, Jung HJ, et al. Etiology of community-acquired pneumonia surveyed by 7 university hospitals. Korean J Infect Dis 1997;29:339-359
55. Yu CW, Park CW, Hwang BY, Song JY, Park O, Sohn JW, et al. Clinical features and prognosis of community-acquired pneumonia in the elderly patients. Korean J Infect Dis 2000;32:212-218
56. Sohn JW, Park SC, Choi YH, Woo HJ, Cho YK, Lee JS, et al. Atypical pathogens as etiologic agents in hospitalized patients with community-acquired pneumonia in Korea: a prospective multi-center study. J Korean Med Sci 2006;21:602-607
57. Song JH, Oh WS, Kang a, Chung DR, Peck KR, Ko KS, et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Agents 2008;31:107-114
58. Lee DD, Song EJ, Lee SM, Lee EY, Kim YS, Lee MK, et al. Frequency of legionella infection in patients with community-acquired pneumonia. Korean J Lab Med 2005;25:416-420
59. Joo CH, Yoon HJ, Nam JH, Moon MS, Cho YK, Woo JH, et al. A prospective multicenter study on the etiological analysis of community-acquired pneumonia in adult patients in Korea: detection of mycoplasma pneumoniae and chlamydia pneumoniae infections. Korean J Infect Dis 2001;33:15-24.
60. Kim MJ, Cheong HJ, Sohn JW, Shim HS, Park DW, Park SC, et al. A prospective multicenter study of the etiological analysis in adults with community-acquired pneumonia: Legionella, Leptospira, Hantaan virus and orientia tsutsugamushi. Korean J Infect Dis 2001;33:24-31.
61. Song HS, Suh JH, Ahn JH, Yoon BI, Lee SJ, Lee MG, et al. The etiological role of legionella pneumophila in patients with community-acquired pneumonia in Korea. Tuberc Respir Dis 2001;50:409-414
62. Lee SJ, Lee MG, Jeon MJ, Jung KS, Lee HK, Kishimoto T. Atypical pathogens in adult patients admitted with community-acquired pneumonia in Korea. Jpn J Infect Dis 2002;55:157-159 (Pubitemid 36150475)
63. Kim JH, Kwak YH, Na BK, Lee JY, Shin GC, Jung HS, et al. Viral etiology of community-acquired pneumonia in Korean adults. Korean J Infect Dis 2001;33:8-14.
64. Lew WJ, Lee EG, Bai JY, Kim HJ, Bai GH, Ahn DI, et al. An Internet-based surveillance system for tuberculosis in Korea. Int J Tuberc Lung Dis 2006;10:1241-7.
65. Lee SH, Hur GY, Jung KH, Lee SY, Lee SY, Kim JH, et al. Clinical investigation of tuberculous pneumonia. Tuberc Respir Dis 2004;57:19-24.
66. Park SD, Chung MH, Lee HM, Kim MK, Kang JS. A Case of scrub typhus in summer presenting as atypical pneumonia. Infect Chemother 2008;40:241-245
67. Kim BN, Bae LG, Kim MN, Park SJ, Woo JH, Ryu J, et al. Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia. Eur J Clin Microbiol Infect Dis 2002;21:35-42. (Pubitemid 34158504)
68. Lee NY, Song JH, Kim S, Peck KR, Ahn KM, Lee SI, et al. Carriage of antibiotic-resistant pneumococci among Asian children: a multinational surveillance by the Asian Network for Surveillance of Resistant Pathogens (ANSORP). Clin Infect Dis 2001;32:1463-1469
69. Farrell DJ, Morrissey I, Bakker S, Felmingham D. Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 2002;50 Suppl S1:3947.
70. Schito GC, Felmingham D. Susceptibility of Streptococcus pneumoniae to penicillin, azithromycin and telithromycin (PROTEKT 1999-2003). Int J Antimicrob Agents 2005;26:479-485
71. Song JH, Jung SI, Ko KS, Kim NY, Son JS, Chang HH, et al. High prevalence of antimicrobial resistance among clinical Streptococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob Agents Chemother 2004;48:2101-2107
72. Lee K, Lim CH, Cho JH, Lee WG, Uh Y, Kim HJ, et al. High prevalence of ceftazidime- resistant Klebsiella pneumoniae and increase of imipenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. in Korea: a KONSAR program in 2004. Yonsei Med J 2006;47:634-645 (Pubitemid 44697294)
73. Shin JH, Jung HJ, Kim HR, Jeong J, Jeong SH, Kim S, et al. Prevalence, characteristics, and molecular epidemiology of macrolide and fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae at five tertiary-care hospitals in Korea. Antimicrob Agents Chemother 2007;51:2625-2627 (Pubitemid 47047352)
74. Kim IS, Ki CS, Kim S, Oh WS, Peck KR, Song JH, et al. Diversity of ampicillin resistance genes and antimicrobial susceptibility patterns in Haemophilus influenzae strains isolated in Korea. Antimicrob Agents Chemother 2007;51:453-460
75. Chang MW, Kim KH, Park ID, Kang KH, Kong EH, Jung MH, et al. Rapid detection of Mycoplasma pneumoniae and antimicrobial susceptibilities of the M. pneumoniae isolates. J Bacteriol Virol 2003;33:183-191
76. Morozumi M, Iwata S, Hasegawa K, Chiba N, Takayanagi R, Matsubara K, et al. Increased macrolide resistance of Mycoplasma pneumoniae in pediatric patients with community-acquired pneumonia. Antimicrob Agents Chemother 2008;52:348-350
77. Arnold FW, Summersgill JT, Lajoie AS, Peyrani P, Marrie TJ, Rossi P, et al. A worldwide perspective of atypical pathogens in community- acquired pneumonia. Am J Respir Crit Care Med 2007;175:1086-1093
78. Robenshtok E, Shefet D, Gafter-Gvili A, Paul M, Vidal L, Leibovici L. Empiric antibiotic coverage of atypical pathogens for community acquired pneumonia in hospitalized adults. Cochrane Database Syst Rev 2008:CD004418.
79. Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005;115:1048-1057
80. Granizo JJ, Gimenez MJ, Barberan J, Coronel P, Gimeno M, Aguilar L. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologie response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials. Clin Ther 2006;28:2061-2069 (Pubitemid 46215745)
81. Lee MY, Ko KS, Oh WS, Park S, Lee JY, Baek JY, et al. In vitro activity of cefditoren: antimicrobial efficacy against major respiratory pathogens from Asian countries. Int J Antimicrob Agents 2006;28:14-18
82. Yi J, Lee JK, Kim EC. In vitro antimicrobial activity of cefditoren pivoxil, an oral cephalosporin, against major clinical isolates. Infect Chemother 2003;35:211-214
83. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399-1408
84. Lautenbach E, Larosa LA, Kasbekar N, Peng HP, Maniglia RJ, Fishman NO. Fluoroquinolone utilization in the emergency departments of academic medical centers: prevalence of, and risk factors for, inappropriate use. Arch Intern Med 2003;163:601-605 (Pubitemid 36314348)
85. Noreddin AM, Marras TK, Sanders K, Chan CK, Hoban DJ, Zhanel GG. Pharmacodynamic target attainment analysis against Streptococcus pneumoniae using levofloxacin 500 mg, 750 mg and 1,000 mg once daily in plasma (P) and epithelial lining fluid (ELF) of hospitalized patients with community acquired pneumonia (CAP). Int J Antimicrob Agents 2004;24:479-484 (Pubitemid 39425161)
86. File TM Jr, Milkovich G, Tennenberg AM, Xiang JX, Khashab MM, Zadeikis N. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia. Curr Med Res Opin 2004;20:1473-1481
87. File TM Jr, Mandell LA, Tillotson G, Kostov K, Georgiev O. Gemifloxacin once daily for 5 days ver sus 7 days for the treatment of community- acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007;60:112-120 (Pubitemid 47073284)
88. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999;159:2562-2572
89. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000;34:446-452
90. Brown RB, Iannini P, Gross P, Kunkel M. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003;123:1503-1511 (Pubitemid 36549769)
91. Mufson MA, Chan G, Stanek RJ. Penicillin resistance not a factor in outcome from invasive Streptococcus pneumoniae community-acquired pneumonia in adults when appropriate empiric therapy is started. Am J Med Sci 2007;333:161-167 (Pubitemid 47181615)
92. Cardoso MR, Nascimento-Carvalho CM, Ferrero F, Berezin EN, Ruvinsky R, Camargos PA, et al. Penicillin-resistant pneumococcus and risk of treatment failure in pneumonia. Arch Dis Child 2008;93:221-225 (Pubitemid 352025494)
93. Song JH, Jung SI, Ki HK, Shin MH, Ko KS, Son JS, et al. Clinical outcomes of pneumococcal pneumonia caused by antibiotic-resistant strains in asian countries: a study by the Asian Network for Surveillance of Resistant Pathogens. Clin Infect Dis 2004;38:1570-1578
94. Hong JH, Lee HS, Jung SH, Kim GW, Eom KS, Lee JM, et al. Prevalence and clinical outcome of penicillin-resistant pneumococcal pneumonia. Tuberc Respir Dis 2003;54:295-303.
95. Hwangbo B, Yoon HI, Lee SM, Choi SH, Yoo CG, Lee CT, et al. Clinical characteristics of pneumococcal bacteremia in adults: the effect of penicillin resistance on the mortality of patients with pneumococcal bacteremia. Tuberc Respir Dis 1999;47:184-194
96. Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, et al. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study-a randomized clinical trial. Clin Infect Dis 2008;46:1499-1509 (Pubitemid 351706729)
97. Bhavnani SM, Ambrose PG. Cost-effectiveness of oral gemifloxacin versus intravenous ceftriaxone followed by oral cefuroxime with/without a macrolide for the treatment of hospitalized patients with community-acquired pneumonia. Diagn Microbiol Infect Dis 2008;60:59-64.
98. Shorr AF, Khashab MM, Xiang JX, Tennenberg AM, Kahn JB. Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patients. Respir Med 2006;100:2129-2136
99. Khashab MM, Xiang J, Kahn JB. Comparison of the adverse event profiles of levofloxacin 500 mg and 750 mg in clinical trials for the treatment of respiratory infections. Curr Med Res Opin 2006;22:1997-2006. (Pubitemid 44663405)
100. File TM. Community-acquired pneumonia. Lancet 2003;362:1991-2001.
101. Torres A, Serra-Batlles J, Ferrer A, Jimenez P, Celis R, Cobo E, et al. Severe community-acquired pneumonia. Epidemiology and prognostic factors. Am Rev Respir Dis 1991;144:312-318
102. Leroy O, Saux P, Bédos JP, Caulin E. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128:172-183 (Pubitemid 40994470)
103. Baddour LM, Yu VL, Klugman KP, Feldman C, Ortqvist A, Rello J, et al. Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am J Respir Crit Care Med 2004;170:440-444 (Pubitemid 39214620)
104. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001;161:1837-42.
105. Arancibia F, Bauer TT, Ewig S, Mensa J, Gonzalez J, Niederman MS, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002;162:1849-1858 (Pubitemid 35051696)
106. Woodhead M, Blasi F, Ewig S, Huchon G, Ieven M, Ortqvist A, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005;26:1138-1180 (Pubitemid 41829947)
107. Committee for The Japanese Respiratory Society guidelines for the management of respiratory infections. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology 2006;11 Suppl 3:S79-133.
108. Craig WA. Pharmacodynamics of antimicrobials: general concepts and applications. In: Nightingale CH, Ambrose PG, Drusano GL, Murakawa T, editors. Antimicrobial phamacodynamics in theory and clinical practice. 2nd ed. New York: Informa healthcare; 2007. p. 1-19.
109. Dunbar LM, Wunderink RG, Habib MP, Smith LG, Tennenberg AM, Khashab MM, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003;37:752-760 (Pubitemid 37153652)
110. Rizzato G, Montemurro L, Fraioli P, Montanari G, Fanti D, Pozzoli R, et al. Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. Eur Respir J 1995;8:398-402.
111. Schönwald S, Skerk V, Petricevic I, Car V, Majerus-Misic L, Gunjaca M. Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia. Eur J Clin Microbiol Infect Dis 1991;10:877-880
112. Menendez R, Torres A, Zalacain R, Aspa J, Martin Villasclaras JJ, Borderias L, et al. Risk factors of treatment failure in communityacquired pneumonia: implications for disease outcome. Thorax 2004;59:960-965 (Pubitemid 39490781)
113. Arancibia F, Ewig S, Martinez JA, Ruiz M, Bauer T, Marcos MA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000;162:154-160 (Pubitemid 30469813)
114. Menéndez R, Torres A, Rodríguez de Castro F, Zalacaín R, Aspa J, Martín Villasclaras JJ, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004;39:1783-1790
115. Celis R, Torres A, Gatell JM, Almela M, Rodríguez-Roisin R, Agustí-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. Chest 1988;93:318-324
116. Sanyal S, Smith PR, Saha AC, Gupta S, Berkowitz L, Homel P. Initial microbiologic studies did not affect outcome in adults hospitalized with community-acquired pneumonia. Am J Respir Crit Care Med 1999;160:346-348 (Pubitemid 29326111)
117. Rosón B, Carratalà J, Fernández-Sabé N, Tubau F, Manresa F, Gudiol F, et al. Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia. Arch Intern Med 2004;164:502-508 (Pubitemid 38314445)